Retrophin Inc. Cmn (RTRX) 17.40 $RTRX Glaxo/J&J

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 11:04 PM

Retrophin Inc. Cmn (RTRX) 17.40 $RTRX

Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 117.01 (+0.01), RTRX: 17.40 (-0.30), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 0.47 (-0.04), RTRX: 17.40 (-0.30), VVUS: 1.19 (-0.03), ARNA: 1.99 (-0.07)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), LGND: 113.74 (-1.34), ACOR: 27.07 (-0.45)

Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 35.29 (-0.02), RTRX: 17.40 (-0.30), TEVA: 53.01 (-0.30), BMY: 72.65 (-0.08)

Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:34AM CDT
Pfizer (PFE) announced top-line results from the OPAL Beyond study on Xeljanz for the treatment of patients with active psoriatic arthritis.
ANIP: 52.05 (-1.64), PFE: 35.29 (-0.02), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 52.05 (-1.64), AZN: 27.97 (-0.99), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)

Business Highlights
By The Associated Press - AP - Mon Jun 06, 4:27PM CDT
___
LNKD: 131.08 (-5.44), FB: 116.62 (-1.94), RTRX: 17.40 (-0.30), GOOGL: 733.19 (-9.33), GOOG: 719.41 (-9.17), UAL: 46.08 (-0.62)

Pharma exec Shkreli pleads not guilty to securities fraud
AP - Mon Jun 06, 4:03PM CDT
NEW YORK (AP) — A pharmaceutical executive who came under fire for jacking up the price of a lifesaving malaria medication has pleaded not guilty to new charges in his securities fraud case.
RTRX: 17.40 (-0.30)

Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 52.05 (-1.64), CLDX: 4.12 (-0.20), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)

Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 52.05 (-1.64), AZN: 27.97 (-0.99), RTRX: 17.40 (-0.30), PBYI: 33.41 (-0.43)

More charges against ex-pharmaceutical executive Shkreli
AP - Fri Jun 03, 8:41PM CDT
NEW YORK (AP) — Federal prosecutors in New York have filed additional criminal charges against a pharmaceutical executive who separately was heavily criticized for raising the price of a lifesaving malaria medication.
RTRX: 17.40 (-0.30)

J&J to Buy Vogue for ~$3.3B, Boost Hair Care Portfolio
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:52AM CDT
Johnson & Johnson (JNJ) has struck a deal to acquire Vogue International for about $3.3 billion in cash in a bid to boost its hair care portfolio.
JNJ: 117.01 (+0.01), PFE: 35.29 (-0.02), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 9:15AM CDT
Alexion Pharmaceuticals (ALXN) announced that ALXN1210 received orphan drug status in the EU for paroxysmal nocturnal hemoglobinuria.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)

Teva's Huntington Disease Drug Receives CRL from the FDA
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:57AM CDT
Teva Pharmaceutical (TEVA) received a complete response letter from the FDA for SD-809 for the treatment of chorea associated with Huntington disease.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), TEVA: 53.01 (-0.30), BMY: 72.65 (-0.08)

Integra (IART): Strong Revenue Growth on Global Prospects
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:16AM CDT
On May 31, 2016, we issued an updated research report on Plainsboro, NJ-based Integra LifeSciences Holdings Corporation (IART).
IART: 76.68 (-0.95), ANIP: 52.05 (-1.64), NEO: 8.40 (-0.62), RTRX: 17.40 (-0.30)

Gilead's (GILD) New HCV Drug Epclusa Wins CHMP Backing
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:04AM CDT
Gilead Sciences' (GILD) Epclusa wins CHMP backing for the treatment of adults with all genotypes (1-6) of chronic hepatitis C virus infection.
GILD: 84.45 (-1.32), ANIP: 52.05 (-1.64), MRK: 56.81 (-0.37), RTRX: 17.40 (-0.30)

The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 37.26 (-1.22), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)

Retrophin to Present at Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 3:30PM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences:
RTRX: 17.40 (-0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jill De Forest Honored: A Journey Through Recruitment

A Force in Recruitment: Jill De Forest There's a name that reverberates through the corridors of executive search and recruitment: Jill De Forest. Recognized by The Inner Circle as the Pinnacle Professional of The Year, De Forest has left a profound mark on the industry with her knack for matching exceptional talent to major brands. Trailblazing through Executive Search...

Outdoor Learning: Sparking Preschool Curiosity Weekly

Rekindling Curiosity in Nature’s Classroom With autumn’s crisp air rolling into Greenville, families have a golden opportunity to take learning beyond the traditional classroom. Archway Academy sees the beauty of this season as a sprawling classroom, one that doesn't confine young minds and bodies. For those of us focused more on dollars and sense, the financial...

Braemar's $358 Million Refinance: A Strategic Shift

Reworking the Debt Load: Braemar's New Move Most days, when a company decides to tinker with its debt, it's like watching paint dry for investors. But with Braemar Hotels & Resorts (NYSE: BHR) announcing a $358 million refinancing package, they're bringing a fresh breath of air to the table. Lemme walk you through why this matters beyond the glossy façade of luxury hotel...

Trimble Revamps SketchUp: Game-Changing Design Innovations

Breaking Down Trimble's Latest Moves in Design Software The design world spins on innovation, and Trimble's pushing the boat out with SketchUp 2027. Unveiled at the swanky Trimble Dimensions User Conference in Las Vegas, this revamp is all about smashing through workflow barriers that have tripped up designers for too long. If you've ever haggled with clunky model...

iHeartMedia Faces Investigation; Shares Plummet 60%

A Sudden Pivot Leaves Shareholders Reeling Nothing like a company blindsiding its investors amid the bustling market chaos. Welcome to the iHeartMedia saga, where promises of profit have turned into a bitter pill for shareholders. On November 9, 2026, the radio giant pulled a fast one by drastically revising its full-year Adjusted EBITDA forecast down to $550...

Straight-Talking Look at Zepp Health's Q3 Preview

Prepping for Zepp Health's Financial Disclosure There's something about earnings season that gets the blood pumping. Maybe it’s the anticipation of numbers that can either make us jump for joy or toss us into a pit of despair. November 22 promises to be an intriguing day for folks with eyes on Zepp Health. They're set to spill the beans on their third-quarter...

Decoding Renters vs. Homeowners Insurance Needs

Breaking Down Policy Differences If you've ever scratched your head over the insurance landscape, join the club. Renters and homeowners insurance each serve a specific role on the financial protection battlefield, and knowing what you're signing up for is downright vital. Oscar Salas from HelloNation lays out the core differences for anyone wise enough to get their heads...

Bell Mare to Elevate Senior Living in DC Suburbs

Bringing Upscale Senior Living to Potomac Nothing like luxury to sweeten the twilight years, huh? The Bell Mare at River Road is gearing up to redefine senior living in Potomac, Maryland, aiming to open its doors in Fall 2028. We're talking 94 swanky units—68 for assisted living and 26 for memory care. And these aren't your grandma's digs. Studio, one-, and two-bedroom...

2026 Shaw Prize: Celebrating Science's Global Impact

Shaw Prize: A Global Stage for Science When it comes to celebrating scientific breakthroughs, the Shaw Prize is the gold standard. On November 10th, 2026, the event unfolded at the iconic Hong Kong Convention and Exhibition Centre, and it was all about honoring those pushing the envelope in science. It’s year 23 for the Shaw Prize, and this ceremony didn’t just hand...

Julian Sawyer Strengthens Wirex Board with Expertise

Ah, the world of digital payments – it's like the wild west out there, constantly evolving and full of promise, but with no shortage of challenges. Enter Julian Sawyer, a name that echoes in the hallowed halls of fintech. And guess what? He's bringing his chops to the Wirex Limited board as an Independent Non-Executive Director. If you're in the market game, better keep...